Voxelotor improves Hb levels, haemolysis markers in younger children with SCD
28 Jul 2021
byElaine Soliven
The use of voxelotor weight-based dosing equivalent to 1,500 mg appears to increase haemoglobin (Hb) levels and decrease clinical markers of haemolysis in patients aged 4–11 years with sickle cell disease (SCD), according to a study presented at EHA 2021.
Voxelotor improves Hb levels, haemolysis markers in younger children with SCD
28 Jul 2021